MyoKardia (MYOK) Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in oHCM

May 21, 2018 7:34 AM
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA

Next Articles